Innoviva, Inc. INVA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
6.59
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $411.3M | — | $307.7M | $195.8M | $1.2B |
| 2024 | $358.7M | — | $296.2M | $188.4M | $691.2M |
| 2023 | $310.5M | — | $246.0M | $140.7M | $675.0M |
| 2022 | $331.3M | — | — | $201.7M | $565.8M |
| 2021 | $391.9M | — | — | $363.8M | $525.9M |
| 2020 | $336.8M | — | — | $313.1M | $607.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Basso Stephen | Chief Financial Officer | 2026-05-20 | Tax withheld | 559 | $22.24 |
| Raifeld Pavel | Chief Executive Officer | 2026-05-20 | Tax withheld | 1,130 | $22.24 |
| Zhen Marianne | Chief Accounting Officer | 2026-05-20 | Tax withheld | 1,127 | $22.24 |
| Linden Josephine | director | 2026-05-18 | Grant | 5,733 | — |
| Linden Josephine | director | 2026-05-18 | Grant | 9,461 | — |
| Basso Stephen | Chief Financial Officer | 2026-05-15 | Grant | 1,123 | — |
| Raifeld Pavel | Chief Executive Officer | 2026-05-15 | Grant | 1,123 | — |
| DiPaolo Mark | director | 2026-05-04 | Grant | 9,786 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.59 (safe)
- Working capital / assets 0.415
- Retained earnings / assets 0.165
- EBIT / assets 0.1
- Equity / liabilities 2.537
Source: SEC EDGAR filings · CIK 0001080014 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.